Brief: Alkermes Announces Positive Topline Results From Enlighten-Early Phase 3B Study Of Lybalvi

Alkermes

08/02/2022 12:51

Feb 8 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM
ENLIGHTEN-EARLY
PHASE 3B STUDY OF LYBALVI® IN PATIENTS EARLY IN ILLNESS
    * ALKERMES - EXPECTS TO SUBMIT RESULTS FROM ENLIGHTEN-EARLY
STUDY
TO A PEER-REVIEWED JOURNAL FOR PUBLICATION
    * ALKERMES PLC - STUDY MET ITS PRE-SPECIFIED PRIMARY
ENDPOINT
    * ALKERMES PLC - FIRST SECONDARY ENDPOINT DID NOT ACHIEVE
PRE-SPECIFIED SIGNIFICANCE LEVEL
    * ALKERMES PLC - A NUMERICAL DIFFERENCE WAS OBSERVED BETWEEN
TREATMENT ARMS ACROSS ALL SECONDARY ENDPOINTS IN FAVOR OF
LYBALVI

Source text for Eikon:  ID:nPn2WMMcxa 
Further company coverage:  ALKS.O 

 ((Reuters.Briefs@thomsonreuters.com;))